Author

A. M. Wengner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Research Focus:benchmarking· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

A. Eggert· 2 shared A. G. Henssen· 2 shared F. F. Pusch· 2 shared G. Seifert· 2 shared H. Dorado Garcia· 2 shared J. H. Schulte· 2 shared J. von Stebut· 2 shared K. Haase· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Eggert

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib

G. Sartori, C. Tarantelli, F. Spriano, E. Gaudio, L. Cascione, M. Mascia, M. Barreca, A. J. Arribas, L. Licenziato, G. Golino, A. Ferragamo, S. Pileri, G. Damia, E. Zucca, A. Stathis, , F. Bertoni

This paper shows that elimusertib, an ATR inhibitor, has anti-lymphoma activity and synergizes with copanlisib, a PI3K inhibitor, in multiple lymphoma models.

bioRxiv · Feb 10, 2023Cancer Biology

Elimusertib outperforms standard of care chemotherapy in preclinical patient-derived pediatric solid tumor models

F. F. Pusch, H. Dorado Garcia, R. Xu, D. Gürgen, Y. Bei, L. Brückner, C. Röefzaad, J. von Stebut, V. Bardinet, M. d. R. Chamorro Gonzalez, A. Eggert, J. H. Schulte, P. Hundsdörfer, G. Seifert, K. Haase, , A. G. Henssen

This paper evaluates elimusertib's preclinical efficacy in pediatric solid tumor models, finding it outperforms standard chemotherapy, especially in alveolar rhabdomysarcoma.

bioRxiv · Nov 10, 2022 · PreprintCancer Biology

Exploiting a PAX3-FOXO1-induced synthetic lethal ATR dependency for rhabdomyosarcoma therapy

H. Dorado Garcia, Y. Bei, J. von Stebut, G. Ibanez, K. Imami, D. Gurgen, J. Rolff, K. Helmsauer, N. Timme, V. Bardinet, R. Chamorro Gonzalez, I. C. MacArthur, F. F. Pusch, C. Y. Chen, J. Schulz, , A. G. Henssen

This study identifies ATR as a synthetic lethal target in PAX3-FOXO1-driven rhabdomyosarcoma, showing ATR inhibition enhances PARP inhibitor efficacy and is tolerated in patients.

bioRxiv · Dec 4, 2020 · PreprintCancer Biology